Cantor Fitzgerald Comments on BCYC FY2025 Earnings

Bicycle Therapeutics plc (NASDAQ:BCYC) – Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Bicycle Therapeutics in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst L. Watsek expects that the company will earn ($4.24) per share for the year. The consensus estimate for Bicycle Therapeutics’ current full-year earnings is ($3.05) per share.

Bicycle Therapeutics (NASDAQ:BCYC) last announced its quarterly earnings results on Thursday, October 31st. The company reported ($0.74) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.04. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The firm had revenue of $2.68 million for the quarter, compared to the consensus estimate of $6.82 million. During the same quarter in the previous year, the business earned ($1.26) earnings per share. The business’s revenue was down 50.0% compared to the same quarter last year.

A number of other equities analysts have also recently commented on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and set a $35.00 price objective on shares of Bicycle Therapeutics in a research report on Friday, November 1st. Stephens reaffirmed an “equal weight” rating and set a $15.00 target price on shares of Bicycle Therapeutics in a report on Wednesday. Needham & Company LLC reissued a “buy” rating and issued a $32.00 price target on shares of Bicycle Therapeutics in a report on Monday, January 13th. B. Riley cut their price objective on shares of Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating for the company in a research report on Friday, December 13th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $33.00 target price on shares of Bicycle Therapeutics in a research report on Monday, January 13th. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $33.25.

Bicycle Therapeutics Trading Down 1.9 %

Shares of NASDAQ BCYC opened at $12.98 on Thursday. The company has a market capitalization of $896.27 million, a P/E ratio of -3.95 and a beta of 0.92. Bicycle Therapeutics has a 12 month low of $12.17 and a 12 month high of $28.67. The stock has a 50 day moving average of $16.56 and a 200-day moving average of $21.23.

Insider Buying and Selling

In other news, CAO Travis Alvin Thompson sold 2,686 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $15.00, for a total value of $40,290.00. Following the completion of the transaction, the chief accounting officer now directly owns 32,146 shares in the company, valued at approximately $482,190. The trade was a 7.71 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Alistair Milnes sold 4,578 shares of the company’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $14.09, for a total transaction of $64,504.02. Following the sale, the chief operating officer now directly owns 100,724 shares of the company’s stock, valued at approximately $1,419,201.16. This trade represents a 4.35 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 33,933 shares of company stock valued at $549,501 over the last 90 days. 8.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. increased its stake in shares of Bicycle Therapeutics by 30.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,329 shares of the company’s stock valued at $131,000 after purchasing an additional 2,191 shares during the last quarter. Avior Wealth Management LLC acquired a new stake in Bicycle Therapeutics in the fourth quarter valued at about $57,000. JPMorgan Chase & Co. grew its position in Bicycle Therapeutics by 26.8% in the third quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company’s stock valued at $191,000 after acquiring an additional 1,782 shares during the last quarter. Principal Financial Group Inc. acquired a new position in Bicycle Therapeutics during the third quarter worth about $10,028,000. Finally, Geode Capital Management LLC lifted its holdings in shares of Bicycle Therapeutics by 79.3% in the third quarter. Geode Capital Management LLC now owns 38,335 shares of the company’s stock worth $868,000 after acquiring an additional 16,958 shares during the last quarter. 86.15% of the stock is currently owned by institutional investors and hedge funds.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.